AMRN - Amarin Corporation plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+0.64 (+2.93%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close21.81
Bid22.44 x 2900
Ask22.45 x 3200
Day's Range21.75 - 22.50
52 Week Range11.78 - 24.67
Avg. Volume8,435,669
Market Cap8.057B
Beta (3Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)-0.19
Earnings DateFeb 24, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.60
  • These Hedge Funds Cashed Out Of Amarin Corporation plc  (AMRN) Too Early
    Insider Monkey

    These Hedge Funds Cashed Out Of Amarin Corporation plc (AMRN) Too Early

    With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was Amarin Corporation plc (NASDAQ:AMRN). Amarin Corporation plc (NASDAQ:AMRN) investors should […]

  • Amarin (AMRN) is a Great Momentum Stock: Should You Buy?

    Amarin (AMRN) is a Great Momentum Stock: Should You Buy?

    Does Amarin (AMRN) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Amarin's Vascepa MAA for Heart Risk Indication Accepted in EU

    Amarin's Vascepa MAA for Heart Risk Indication Accepted in EU

    The EMA validates Amarin's (AMRN) regulatory application seeking approval for Vascepa as a treatment to reduce risk of cardiovascular events.

  • Do Options Traders Know Something About Amarin (AMRN) Stock We Don't?

    Do Options Traders Know Something About Amarin (AMRN) Stock We Don't?

    Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

  • Heart Drugs Are Having a Moment

    Heart Drugs Are Having a Moment

    (Bloomberg Opinion) -- Drugmakers have spent years de-emphasizing heart medications in favor of higher-priced treatments for cancer and rare diseases. As America enters its most caloric season, it looks like that is starting to change, for now. Novartis AG made a particularly large commitment Sunday with its $9.7 billion purchase of Medicines Co. and its promising new cholesterol drug. Meanwhile, biotechnology company Amarin Corp.’s bet on its fish-oil-derived capsule Vascepa is starting to pay off: Its shares soared earlier this month after a Food and Drug Administration panel recently suggested the pill — which was shown to cut cardiac risk in a huge trial last year — be made available to millions of additional patients. Heart medicines are also key pipeline components or sales drivers at a number of big pharmaceutical companies as well, from Merck & Co. and Bayer AG to Pfizer Inc.Investment in cardiac medicines is positive for patients and public health; after all, heart disease remains the most significant cause of death in the U.S. There’s a reason that drugmakers had backed away, however. These companies will have to navigate a harsh market environment to keep this mini-renaissance alive. Effective heart disease medicines, including statins for cholesterol and drugs for high blood pressure, have become much cheaper as generic options have hit the market. That’s excellent for patients and health budgets, as expanded use of these drugs has been impactful enough to  slow Medicare spending growth. But it makes things difficult for newer, higher-priced medicines to make inroads. Next-generation drugs need to prove they can add something on top of or substantially outperform cheaper options to have a chance at anything but niche success. They sometimes still struggle even if they do. Cardiovascular drugs take time to have an impact, and the American health-care system isn’t patient.  People change health insurance all the time as they swap or lose jobs, pick a new plan, or have one selected for them. Health plans often focus on annual costs and don’t always want to pay extra for an uncertain benefit that might eventually save someone else money. That tendency is most pronounced in large markets, where rapid uptake of a new drug translates into substantial spending increases.Two relatively new cholesterol drugs — Praluent, from Sanofi and Regeneron Pharmaceutical Co., and Amgen Inc.’s Repatha —  are the most significant recent cautionary tales. They were both approved in 2015 with high expectations and are effective medications, but the market balked at their high price and threw up barriers to access. The result was a glacial launch. Sales remain sluggish even after major price cuts.  Medicine Co.’s inclisiran lowers cholesterol at a similar rate by using the same drug target as those medicines but requires far less frequent dosing. Novartis will have to find out whether convenience is enough to command a premium price and avoid the same commercial fate. As for Amarin, a drug-price watchdog called Vascepa a rare cost-effective option for heart disease earlier this year. That doesn’t guarantee a rapid ascent to blockbuster sales. The drug’s future is partially in the FDA’s hands. The exact language of the agency’s expanded approval will help determine how many new patients will get access. The bigger part is arguably once again up to health plans. They will decide how strictly to interpret the FDA’s guidelines, and whether patients will have to jump through hoops to get the medicine. The size of the potential patient population may inspire them to clamp down, cost-effectiveness be damned. The barriers to heart drugs are navigable. Novartis was likely inspired to pay up for Medicines because it managed the feat with its heart-failure treatment Entresto. Sales of the drug started extremely slowly, but are now growing at a respectable clip. There is a clear opportunity in this somewhat neglected space. Profiting from it might require a high risk tolerance and an extra measure of patience. To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at©2019 Bloomberg L.P.

  • GlobeNewswire

    European Medicines Agency Accepts for Review Marketing Authorization Application for Amarin’s Icosapent Ethyl (Vascepa®) for Reduction of Cardiovascular Risk in High-Risk Patients, as Reflected in REDUCE-IT® Study

    Amarin Corporation plc (AMRN), a pharmaceutical company focused on improving cardiovascular health, announced today that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) seeking approval for icosapent ethyl (brand name Vascepa® in the United States) as a treatment to reduce the risk of cardiovascular events in high-risk patients who have their cholesterol levels controlled with statin treatment, but have elevated triglycerides,135 mg/dL or above, and other cardiovascular risk factors. The validation confirms the submission for Vascepa is sufficiently complete for the EMA to begin its review procedure, which is currently expected to be completed before the end of 2020.

  • Amarin Corporation plc's (NASDAQ:AMRN) Shift From Loss To Profit
    Simply Wall St.

    Amarin Corporation plc's (NASDAQ:AMRN) Shift From Loss To Profit

    Amarin Corporation plc's (NASDAQ:AMRN): Amarin Corporation plc, a pharmaceutical company, engages in the development...

  • Why A Stock Market Correction Would Be A Good Thing Right Now: Advisor
    Investor's Business Daily

    Why A Stock Market Correction Would Be A Good Thing Right Now: Advisor

    Financial advisor Patrick Healey shares why a small stock market correction is needed in the current investing environment — and how to deal with investor FOMO.

  • Top Ranked Momentum Stocks to Buy for November 27th

    Top Ranked Momentum Stocks to Buy for November 27th

    Top Ranked Momentum Stocks to Buy for November 27th

  • Why Did Farallon Capital Get Out of These 3 Biotech Stocks?

    Why Did Farallon Capital Get Out of These 3 Biotech Stocks?

    Since 1986, Farallon Capital has built a proven record for success, mainly from steady hands at the helm and consistent returns for investors. The firm was founded by Tom Steyer, with $15 million in initial capital, and when he retired as managing director in 2012 Farallon had grown to hold over $20 billion in assets under management.Steyer’s successor, Andrew Spokes, has continued the firm’s strategy of ‘absolute return’ investing, assuming every investment has a guaranteed return. As far as stocks are concerned, this investment strategy tends toward the conservative – but it also tends to ensure a good return.So, it makes sense that Farallon would get rid of underperforming or overly risky stocks. In the last quarter, the firm backed out of three high-profile biotech firms.Let’s dive into the TipRanks database to learn more about the doubts and why Farallon is backing out of these biotechs.Sarepta Therapeutics (SRPT)This Massachusetts-based firm takes a focus on genetic disorders, especially muscular dystrophy. Sarepta has one approved product, Exondys 51, a treatment for Duchenne muscular dystrophy, and approved for patients with a confirmed mutation in the DMD gene. With another 16 projects in the pipeline, Sarepta is well positioned for the future. The company is a collaborator on an additional 9 projects.Biotech is a sector with inherent high overhead, high risk, and long lead times to profitability, so Sarepta, like many biotechs focused on clinical phase research, operates at loss. In Q3, the company’s EPS loss increased by 103% year-over-year, to $1.14, even though revenues, at $99 million, showed a 26% yoy gain. The quarterly report noted increased expenditures as the root cause of the increased earnings loss.Interestingly, Farallon divested 500,000 shares – the firm’s entire position in Sarepta. It was a major move by a major fund, that signals a serious lack of confidence in SRPT going forward.At least one Wall Street analyst would agree with Farallon’s position. Hartaj Singh, writing from Oppenheimer, set a Hold on the stock. He wrote, “We believe that with management's focus on early stage gene therapy trials, investor sentiment is slowly shifting to a more skeptical stance on other projects." The analyst added, "While management's (and the Street's) focus has been on the development pipeline, namely SRP-9001, we have highlighted the role a golodirsen CRL could have on the P&L in the medium term. Updates on regulatory actions remain a potential catalyst for 2019, but we keep vigilant on the progress of commercial supply development for SRP-9001. Feasibility of these outlined timelines could be put to the test in 2020." (To watch Singh's track record, click here)Other analysts might have to seriously disagree with Singh. The Street considers Sarepta stock a Strong Buy. According to TipRanks analytics, out of 13 analysts, 12 are bullish, while only one is sidelined. The consensus price target stands at $184.91, showing a 73% upside from the current share price. (See Sarepta stock analysis on TipRanks)Exelixis (EXEL)Located in Alameda, not far from Silicon Valley, Exelixis develops medications for the treatment of a variety of cancers. Unlike many small- to mid-cap biotech companies, Exelixis operates at a profit, thanks to three approved medications on the market. Two of the drugs, Cabometyx and Cometriq, are brand names for cabozantinib, used to treat thyroid and renal cancers, while the third, Cotellic, is used for treatment of melanoma.Having several products on the market for common cancers puts EXEL stock in the black. The company has been running a profit and beating earnings expectations since early in 2018. In its most recent quarterly report, EXEL posted an EPS of 31 cents, beating the 20-cent forecast by an impressive 55%. Still, the EPS was down 24% from the year-ago quarter. The drop in year-over-year earnings came even as revenues, at $271.7 million, increased 20% in the same period.The slide in earnings, despite strong revenues, indicate slower sales than expected – and that induced Farallon to shed 42% of its Exelixis holdings. In all, Farallon sold off 1.25 million shares of EXEL in Q3. Farallon still owns more than $28 million worth of EXEL. It will be interesting to see what the fund does with this stock going forward.5-star BMO analyst George Farmer looks at EXEL and says Hold. He notes the company’s profits, but is cautious on sales. He noted, “Weak Cabometyx sales of $187M, well below ours/consensus of $203M/ $198M, were recorded in spite of a 4.5% price increase last July. We believe this result, ostensibly due to a backlog of patients slow to progress, creates a new overhang on shares…” (To watch Farmer's track record, click here)However, it looks like other analysts aren’t ready to tap out just yet. This stock’s Moderate Buy consensus rating is based on 6 Buys and 3 Holds given in the past three months. Shares are priced at $16.80 and have an average price target of $24.78, indicating upside potential of 48%. (See Exelixis stock analysis on TipRanks)Amarin (AMRN)The company’s omega-3 based drug, Vascepa, is available by prescription as a treatment for hypertriglyceridemia, an indicator for heart disease, and has been shown to have a clear beneficial effect in preventing heart attack. Vascepa was approved and put on the market in 2013, and forecasts show it reaching well over $2 billion in sales by 2024. However, the omega-3 niche is starting to fill up, and Vascepa is facing increasing competition.That competition has not impacted Amarin’s profits – yet. The company’s Q3 results showed $112 million in revenues, a 103% year-over-year gain, and the company has $677 million in cash-on-hand. Vascepa prescription were up 9.9% from Q2, to 865,000 orders.Amarin saw its shares surge as high as 50% this month. The boost came on the heels of FDA AdCom vote in favor of extending the label on the company’s flagship drug, Vascepa, to include patients at risk of a heart attack and other major adverse cardiovascular events. The FDA is set to make a final decision on December 28, 2019.Spokes, however, saw risk here, and Farallon’s sale of Amarin shares was its largest biotech divestment. The firm sold off 2,249,400 shares in AMRN in Q3, reducing its holding by 53% to just over 2 million shares.Two Wall Street analysts become more skeptical about Amarin's valuation earlier this month. Joel Beatty of Citigroup, wrote, “We believe Vascepa is an effective drug and anticipate sales accelerating significantly over the next year, however, we believe this is now already priced into the stock.” Beatty downgraded AMRN from Buy to Hold, although his $27 target suggests an upside of 29% for AMRN. (To watch Beatty's track record, click here)Oppenheimer analyst Leland Gershell is even more downbeat on Amarin. He said, in his recent initiation of coverage report, “We believe that a ~12-month stream of late-stage competitor data starting next month will increasingly weigh on shares as these products, which we believe offer superior profiles, are factored into models.” Gershell’s price target, $7, implies a strong 66% downside here. (To watch Gershell's track record, click here)Overall, Amarin still gets a Moderate Buy from the analyst consensus, with 7 Buys, 2 Holds, and 1 Sell set in recent weeks. The stock has a $27.50 average stock-price forecast, indicating a 35% upside from the $20.42 trading price. (See Amarin stock analysis on TipRanks)

  • Amarin's Shares Down on Underperform Rating by Oppenheimer

    Amarin's Shares Down on Underperform Rating by Oppenheimer

    Amarin's (AMRN) shares decline as the independent advisory firm, Oppenheimer, initiates coverage with an Underperform rating on the back of concerns related to its marketed drug, Vascepa.

  • Hedge Fund Innovator Joseph Edelman Doubles Down on These 3 Biotech Stocks

    Hedge Fund Innovator Joseph Edelman Doubles Down on These 3 Biotech Stocks

    More than 500 biotech companies operate in the US, doing their part to make it the world’s hub for innovation. Only about 20 of them turn a profit, though, highlighting the dangers of the biotech sector. High overhead, long research terms, and the uncertainties of clinical testing and regulatory approval all weigh on them, making biotech at once the riskiest and most potentially profitable of the stock market’s segments.Enter Joseph Edelman. The hedge fund veteran started Perceptive Advisors back in 1999 with just $6 million, and his hedge has grown to hold over $5 billion in assets under management today. Edelman’s fund’s flagship, the Perceptive Life Sciences Fund, specializes in small- and mid-cap biotech companies. That Edelman knows how to spot the winners is clear from the Life Sciences Fund’s annualized gains of 30% since its inception.In the words of Brad Loncar, of Loncar Investments, biotech is the “most volatile sector in the stock market… More so than any industry, it’s important to be diversified... Even excellent companies with great science fail all the time and have big setbacks, because it’s that difficult of a business.” Edelman has thrived in this difficult business for the last twenty years, and in his most recent 13F filing, for the quarter ending this past September 30, he doubled down on three companies.We’ve looked up each in the TipRanks database, to find a line on why.Amarin Corporation (AMRN)A mid-cap company, valued at $7 billion, Amarin is the largest of the companies on this list. Perceptive bought over 1.4 million shares of AMRN in the third-quarter, bringing the fund’s total holding to 7.6 million shares. Edelman’s fund first bought into Amarin in Q3 2018, and now holds more than $173 million of AMRN shares.It’s not hard to understand why a biotech-focused hedge fund would go large on Amarin. The company has only one product on the market, but that one is a true humdinger. The medication, Vascepa, is an omega-3 based treatment for hypertriglyceridemia, with a proven record of reducing triglycerides in adult patients. Vascepa has been commercially available since 2013, and is predicted to reach $2.2 billion in annual sales by 2024.Vascepa’s success in the open market is clear from Amarin’s quarterly results. The company reported Q3 revenues of $112 million, up 103% from the year-ago quarter, and a cash-on-hand position of $677 million. Underneath these strong numbers was equally strong prescription performance for Vascepa – the company reported over 865,000 new and repeat orders for the drug in the quarter, up 9.9% sequentially. Importantly, the FDA is set to make a final decision on a label expansion for Vascepa to include patients at risk of a heart attack and other major adverse cardiovascular events (MACE). The company should get either green or red light by December 28, 2019. AMRN shares have been getting plenty of love lately from Wall Street’s analysts, but also some skepticism.Louise Chen, writing from Cantor, says, “The peak sales potential of Vascepa is underappreciated and that upward earnings revisions should drive Amarin shares higher.” Her price target of $35 suggests an upside of over 70% to the stock. (To watch Chen's track record, click here)Jefferies analyst Michael Yee is also bullish on AMRN, citing the upcoming FDA decision. He states, “While some investors do not like the risk/reward debate on the December 28 potential FDA approval and label wording, [we are] not too concerned about the exact wording. Based on commentary by the FDA at the end of the panel, [we think] the agency might be broader on the label than some investors expect. Expect Amarin to rise toward $30 per share...” Yee’s price target implies a 51% upside. (To watch Yee's track record, click here)Meanwhile, Amarin stock has hit a new 52-week high last Friday, with a valuation that almost reached the $9 billion level. Indeed, the stock's valuation is way too high for Oppenheimer analyst Leland Gershell who initiated coverage on AMRN with an "underperform" rating (i.e. Sell) and a $7.00 price target. Gershell opined, "We forecast sales growth to underwhelm and heavy selling costs to impede profitability. Furthermore, we believe that a ~12-month stream of late-stage competitor data starting next month will increasingly weigh on shares as these products, which we believe offer superior profiles, are factored into models. While some may regard AMRN as a probable M&A target, we see the likelihood of this outcome as only shrinking with time." Gershell's price target implies about 60% downside from current levels.Overall, the word on the Street rings largely bullish on this fish oil drug maker, with TipRanks analytics demonstrating AMRN as a Buy. Out of 10 analysts tracked in the last 3 months, 7 are bullish on Amarin stock, 2 remain sidelined, and 1 is bearish on the stock. With a return potential of nearly 35%, the stock's consensus target price stands at $27.30. (See Amarin stock analysis on TipRanks)Solid Biosciences (SLDB)This small-cap biotech focuses on developing treatments for Duchenne muscular dystrophy (DMD), the most common form of the devastating genetic disorder. DMD is a sex-linked recessive trait, and affects about 1 in 5,000 male children at birth. SLDB’s main product, drug candidate SGT-001, is at the Phase I/II stage of development.Clinical failures and safety concerns have dogged Solid through much of this year. Back in May, SGT-001 saw disappointing numbers in an early testing readout, leading to a 64% drop in share value for SLDB – but also to an increased dosage in ongoing test. That led to a ‘patient event’ in May, in which a test subject reported an adverse reaction. The FDA stepped in and put a clinical hold on the drug at that point.The company was able to address FDA concerns and resume testing, but last week it saw another FDA clinical hold. This hold was again the result of a patient experiencing an ‘adverse event.’ According to reports, the patient suffered kidney damage. SLDB shares, which had not truly recovered from February’s hit, dropped an additional 64% on the news.With this as background, we can look at Edelman’s purchase. His fund bought more than 2.8 million shares of SLDB in Q3, bringing the total holding to 6.7 million shares. At the end of the quarter, the shares were priced near $10 each; they are now trading at just $3.68. This is down 64% from the end of Q3. Edelman has a history of holding on to his biotech purchases for a long time, regardless of performance or clinical testing results. He has said that "an investor who doesn’t like risk should not be in this business."Solid hasn’t been getting much love on Wall Street analyst lately. Credit Suisse analyst Martin Auster writes of the SGT-001 program, “This is the second time that the program has had a clinical hold, which supports our view that the drug has a more challenging safety profile relative to competitors. While the company tried to refocus investors on the upcoming biopsy data from the first 2 high dose patients later this year, we see investors as likely discounting this efficacy update until the company receives clarity on the path forward for the program and shores up its balance sheet.” Auster’s $2 price target implies a downside risk to the stock of 45%. (To watch Auster's track record, click here)All in all, the analyst consensus on SLDB is a Moderate Sell, based on 2 recent sell ratings issued in the past 3 months. Analysts are worried about the company’s path forward when its prime drug candidate has lost the trust of regulators. (See SLDB stock analysis on TipRanks)VBI Vaccines (VBIV)VBI aims at developing a new generation of vaccines, targeting, in the company’s words, ‘unmet needs in infectious disease and immune-oncology.’ The company’s most advanced programs are prophylactic treatments for Hepatitis B, Sci-B-Vac, which has been approved for use in 10 countries, and VLP, which is in Phase 3 testing.In the immune-oncology field, the company has VBI-1901 in testing for patients with recurrent glioblastoma. The company’s Chief Medical Officer said, “We are encouraged by the data we’ve seen to-date in Part A of the study.” VBI-1901 is now in Phase 1 testing.Also in Q3, Edelman and his Life Sciences Fund bought 20 million shares of VBIV, increasing their holding of the company by 78%. The fund now holds 45.9 million shares of the company, with a value of $27 million. This is a significant drop in value from the $45 million recorded at the end of last quarter.Canaccord analyst John Newman sees upside potential in this small company. He writes, “VBIV expects to present top-line data in January from the CONSTANT Phase 3 trial, which we expect to be positive… We expect the data will include key immune repression measures such as geometric mean concentration (GMC) of antibodies across the three independent manufactured lots of Sci-B-Vac.” Newman does, however, lower his price target to $4. Even so, his implied upside is an impressive 577%. (To watch Newman's track record, click here)VBI Vaccines has received 2 recent reviews, both Buys. Shares are selling for minimal 59 cents, but the stock has a $3.50 price target which suggests an-opening 466% upside potential. (See VBI Vaccines stock analysis on TipRanks)

  • MarketWatch

    Amarin shares fall 10% on analyst concerns about growth

    Shares of Amarin Corp. dropped 10% in morning trading after Oppenheimer analysts initiated coverage Tuesday at underperform. They said that while they anticipate a label expansion for Vascepa, Amarin's prescription fish oil-derived medication, they also expect "sales growth to underwhelm and heavy selling costs to impede profitability. Vascepa is currently approved to reduce triglycerides, but a Food and Drug Administration advisory committee last week voted 16-0 in favor of expanding the label to say the drug lowers the risk of cardiovascular events like heart attacks or strokes. Further, Oppenheimer's view is that the possibility of Amarin being acquired is "only shrinking with time." The FDA is expected to make its decision on Vascepa by Dec. 28. Shares of Amarin are up 60% year-to-date, while the S&P 500 has risen 24%.


    Amarin Stock Is Sinking After a Bearish Assessment of Its Heart Drug

    Oppenheimer analyst Leland Gershell argues that the stock, which closed Tuesday at $22.73, will fall to $7 within 18 months.

  • Benzinga

    The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan ...

  • Oppenheimer Sees Doom and Gloom in Amarin (AMRN) Stock

    Oppenheimer Sees Doom and Gloom in Amarin (AMRN) Stock

    Buoyed by optimism over the label expansion of Amarin's (AMRN) flagship drug, Vascepa, the fish oil drug maker's stock has run off to the races -- up over 60% year-to-date. But how long can that last? This afternoon, US investment giant Oppenheimer predicted an imminent crash in Amarin shares.Oppenheimer analyst Leland Gershell and his team joined a small, but vocal camp of bearish folks waving investors away from Amarin stock. Gershell initiated coverage on AMRN with an "underperform" rating and a $7.00 price target, predicting the stock will drop about 70% in the next 12 months. (To watch Gershell's track record, click here)Amarin submited sNDA to the FDA seeking label expansion of its fish oil drug Vascepa to include patients at risk of a heart attack and other major adverse cardiovascular events (MACE). The FDA is scheduled to make a decision by December 28, 2019, and an FDA advisory committee already unanimously (16-0) recommended approval.However, Gershell highlights the stock’s lofty valuation as particularly problematic. The analyst noted, "With a ~$7.3B EV, we believe AMRN’s valuation reflects expectations that, following an anticipated near-term label expansion of sole omega-3 product Vascepa: 1) sales will inflect and grow to $2B+ by 2023-24; and 2) operating margins will meaningfully improve. In contrast, we forecast sales growth to underwhelm and heavy selling costs to impede profitability. Furthermore, we believe that a ~12-month stream of late-stage competitor data starting next month will increasingly weigh on shares as these products, which we believe offer superior profiles, are factored into models. While some may regard AMRN as a probable M&A target, we see the likelihood of this outcome as only shrinking with time."Based on the word of the Street, Gershell seems to be the sole bear running loose here. Out of 10 analysts polled by TipRanks in the last 3 months, 7 rate AMRN stock a Buy, while two say Hold, and one recommends Sell. The 12-month average price target stands at $27.30, marking a 20% upside from where the stock is currently trading. (See Amarin stock analysis on TipRanks)

  • Thomson Reuters StreetEvents

    Edited Transcript of AMRN earnings conference call or presentation 5-Nov-19 12:30pm GMT

    Q3 2019 Amarin Corporation PLC Earnings Call

  • GlobeNewswire

    Amarin Highlights Key REDUCE-IT®-Related Data Presented at American Heart Association 2019 Scientific Sessions

    Amarin Corporation plc (AMRN), a pharmaceutical company focused on improving cardiovascular health, hosted a webcast today to discuss important data with study authors who presented at the American Heart Association 2019 Scientific Sessions, November 16-18. The data covered related to Vascepa® (icosapent ethyl) capsules, the landmark clinical outcomes study REDUCE-IT®[1] , as well as the cardiovascular risk of patients with elevated triglycerides, a type of fat in the blood.

  • How Much Higher Can Amarin (AMRN) Stock Go Following FDA Approval?

    How Much Higher Can Amarin (AMRN) Stock Go Following FDA Approval?

    Amarin (AMRN) investors received a nice gift going into the weekend, after shares of the biopharma increased by almost 12% on Friday. The boost came on the heels of Thursday’s FDA AdCom vote in favor of extending the label on the company’s flagship drug, Vascepa, to include patients at risk of a heart attack and other major adverse cardiovascular events. The FDA is set to make a final decision on December 28, 2019.Vascepa is an FDA approved fish oil capsule used alongside a healthy diet to help lower fats (triglycerides) in the blood. The talk now turns to what level of risk the label should include. Although the panel was unanimous in its agreement on secondary prevention patients (patients already being treated for cardiovascular events), the panel was split on whether the label should include primary prevention patients (high risk patients yet to receive any treatment). The REDUCE-IT study on which the results were based wasn’t broad enough to adequately convince the panel that the label should include primary prevention for high risk patients.Nevertheless, Stifel analyst Derek Archila thinks the AdCom’s vote is a positive one, noting, “We believe approval in secondary prevention alone offers an addressable market that is at least ~10-15 million patients for Vascepa making us comfortable with our ~$3 billion in peak sales estimate… Our diligence with regulatory experts gets us comfortable in an FDA approval for a Vascepa label expansion to include reduction in CV risk based on the REDUCE-IT results in early 2020, which should effectively increase its addressable market size by a factor of 20.” The analyst continued, "We remain buyers here as we see upside to to the mid-$20 range based on the positive panel and think if the FDA grants a label inclusive of primary prevention."To this end, Archila reiterated his buy rating on AMRN stock along with a price target of $26.00, which implies about 15% upside from current levels. (To watch Archila’s track record, click here)4-star H.C. Wainwright analyst Andrew Fein further enhances the bull case, saying, "Based on: (1) the unanimously positive AdCom; and (2) revisiting our projections informed from our encouraging physician survey on market demand for an expanded label, our projected penetrations led us to the same $51 price target based on a more substantiated patient number, and did not differ significantly from our previous estimates. Based on these conclusions, our price target remains unchanged and we believe that with the momentum of the positive AdCom, anticipated expanded label approval could move the stock towards our $51 price target, in our view."If everything goes as Fein planned, AMRN stock could rise by a whopping 112% over the next 12 months. (To watch Fein's track record, click here)With a background like that, it’s no wonder that AMRN has attracted rave reviews from Wall Street analysts. The stock's consensus rating is Strong Buy, with 7 analysts giving it the thumbs up in the last three months, while only 2 remain sidelined. Shares sell for $22.60, and the average price target is $29.56; this indicates a potential upside of 30%. (See Amarin stock analysis on TipRanks)

  • GlobeNewswire

    Amarin’s John Thero Awarded EY Entrepreneur of The Year® 2019 Life Sciences National Award

    Amarin Corporation plc (AMRN), a pharmaceutical company focused on improving cardiovascular health, announced today that John F. Thero, president and chief executive officer of Amarin, has been named EY’s 2019 Entrepreneur of The Year National Award® for Life Sciences. Mr. Thero was named EY’s Entrepreneur of The Year 2019 Award for Life Sciences in the New Jersey Region in June 2019, thus placing him in the running for the national award. “This award is a great honor, especially in light of the many outstanding people, and the achievements of their companies, that were considered,” stated Mr. Thero.


    Matinas Rides Amarin's Coattails as Vascepa Wins FDA Panel Vote

    Amarin's omega 3 fatty acid drug Vascepa is now closer to being blockbuster with an FDA panel vote win Continue reading...


    Amarin Stock Has Soared. Citi Thinks It’s Gone Far Enough.

    Citi downgraded the stock after a blockbuster week that brought positive news for the biotech’s heart drug, Amarin.

  • Will Amarin Continue to Surge Higher?

    Will Amarin Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Amarin.

  • This Biotech Stock Broke Out Bullishly On A Key FDA Recommendation
    Investor's Business Daily

    This Biotech Stock Broke Out Bullishly On A Key FDA Recommendation

    Amarin stock topped a buy point Friday after a Food and Drug Administration advisory committee unanimously supported a second use for the biotech company's key drug, Vascepa.

  • Benzinga

    Analyst: Peak Sales Potential Of Amarin's Vascepa Underappreciated

    Amarin Corporation (NASDAQ: AMRN) traded higher after the FDA's Endocrinologic and Metabolic Drug Advisory Committee voted 16-0 to recommend approval of label expansion for Vascepa capsules to include reduction in the risk of cardiovascular, or CV, events in high-risk patients. Vascepa was initially approved in 2012 as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The Adcom reviewed the drug based on the results from the Phase 3 REDUCE-IT CV outcomes trial, which showed that the addition of Vascepa to statin therapy brought down the risk of cardiovascular events by 25% compared to statins along with mineral oil, which was used as placebo.